The mucus layer covering all mucosal surfaces in our body is the first barrier encountered by drugs before their potential absorption through epithelial tissues, and could thus affect the drugs' permeability and their effectiveness. Therefore, it is of key importance to have in vitro permeability models that can mimic this specific environment. For this purpose, the novel mucus phospholipid vesicle-based permeation assay (mucus-PVPA) has been developed and used for permeability screening of drugs and formulations. The model proved to be stable under the chosen conditions and demonstrated the ability to discriminate between compounds with different chemical structures and properties. Overall, a decrease in drug permeability was found in the presence of mucus on top of the PVPA barriers, as expected. Moreover, mucoadhesive (chitosan-coated) and mucopenetrating (PEGylated) liposomes were investigated in the newly developed model. The mucus-PVPA was able to distinguish between the different liposomal formulations, confirming the penetration potential of the tested formulations and the related drug permeability. The mucus-PVPA model appears to be a promising in vitro tool able to mimic the environment of mucosal tissues, and could therefore be used for further drug permeability screening and formulation development.
Introduction
The mucus layer covering mucosal epithelia is the first barrier encountered by many drugs and formulations when entering the body. This layer could thus potentially limit the effectiveness of most drug delivery systems (Groo and Lagarce, 2014) . Mucus is found on many epithelial surfaces such as the gastrointestinal tract (GI), the respiratory tract, the eye and the female genital tract; its composition, structure and thickness differ according to the different locations in the body (Friedl et al., 2013; Leal et al., 2017; Sigurdsson et al., 2013) .
The main components of mucus are water, glycoproteins (i.e. mucins), free proteins, salts and lipids (Groo and Lagarce, 2014 ). An important role is played by mucins, negatively charged glycoproteins (polypeptide backbone with oligosaccharide side chains), which are secreted by mucosal glands and goblet cells (Leal et al., 2017; Sigurdsson et al., 2013) . The structure of the mucin gel can hinder the diffusion of drugs (Boegh and Nielsen, 2015) by two main mechanisms, namely the interaction and size filtering (Olmsted et al., 2001) .
Transmucosal drug delivery gained increasing attention in the past two decades. Various strategies have been proposed to improve the mucosal permeability of drugs, including mucoadhesive and mucopenetrating systems, such as liposomes (Leal et al., 2017) . Therefore, to properly tackle the screening of new drugs and optimization of novel mucosal formulations, it is of key importance to exploit in vitro tools comprising mucus to better understand its impact on drug permeation and absorption and to better predict the fate of a drug in vivo. Many models have been developed to study the effect of the sole mucus layer on drug permeability, without the presence of an artificial membrane. Some of them comprise the use of native mucus and some others exploit the use of commercially available mucins in different types of media (Khanvilkar et al., 2001 ; Legen and Kristl, 2001; Matthes et al., 1992) . However, it has to be noted that the removal of mucus from its physiological 6 (Billerica, Massachusetts) and the Nucleopore track-etch membrane filters (0.4 and 0.8 µm pore size) were purchased from Whatman (part of GE Healthcare, Oslo, Norway).
PVPA barriers preparation
The PVPA barriers were prepared by depositing egg-phospholipid liposomes on top of cellulose ester filters by centrifugation followed by a freeze-thaw cycle according to a method previously described (Naderkhani et al., 2014a ).
Mucus barrier
Different concentrations of mucin (10, 20 and 40 mg/mL) were used as a model for the mucus layer. These suspensions were obtained by the hydration of mucin from porcine stomach type III with phosphate buffer saline (PBS) pH 7.40. The viscosity of the mucus was measured at room temperature on HAAKE ViskoTester 7 plus (Thermo, Hafrsfjord, Norway) using spindle TL5. In the in vitro permeability studies, the mucin suspension was directly pipetted on top of the PVPA barriers before the addition of the drugs or formulation to be tested. The drug solutions/formulations were carefully added on top of the mucus layer in the donor compartment in order to prevent mixing of the two layers. The division of the two layers was visibly distinct.
In vitro permeability study using the mucus-PVPA
The permeability of different drugs/marker (calcein, CAL; atenolol, ATN; ibuprofen, IBP; indomethacin, IND; naproxen, NPR; metronidazole, MTR; Table 1 ) was investigated at room temperature (23-25 °C) in the presence and absence of mucus following the procedure previously described (Naderkhani et al., 2014a) . In the experiments performed in the presence of mucus, 50 µL of mucin 10 mg/mL were added, if not stated otherwise, before the careful addition of drug/marker. To maintain sink conditions, the inserts were moved to a new acceptor compartment at certain time intervals for 5 hours. After ended experiment, the electrical resistance was measured to confirm the integrity of the barriers and the samples collected as previouslu described (Flaten et For each compound the experiment was performed at least in triplicates (6 inserts for each parallel) and the apparent permeability coefficient (Papp) was calculated with the equation derived from Fick's law for steady state conditions:
where /d is the slope at the steady-state conditions (nmol/s), A represents the surface area of the PVPA barriers (cm 2 ) and Cd is the concentration of the compound in the donor compartment (nmol/mL).
As earlier described by our group (Flaten et al., 2006a, b) , the concentrations of the drugs investigated in the study were chosen in order to reach a concentration in the acceptor compartment that was below the solubility limits and thus to obtain sink conditions. The permeability of different drugs/marker (Table 1) was measured in the absence and presence of mucus at 37 °C and compared to the one obtained at room temperature (23-25 °C) to evaluate possible changes in permeability due to elevated temperature. Different concentrations of mucin (10, 20 and 40 mg/mL) were tested to estimate their effect on the permeability of the tested compounds. Moreover, different volumes of mucus (mucin 10 mg/mL; mucus volume range: 20-50 µL) were deposited on top of the PVPA barriers, and the permeability of naproxen was measured to assess if the different mucus' volumes would have any effect on the drug's permeability.
PVPA barriersmucus interaction

Phospholipid assay
In order to determine any changes in the barriers' integrity caused by the addition of mucus on top of the PVPA barriers, the amount of phospholipids released after the addition of the mucus layer was measured by the modified phosphorus assay (Bartlett, 1959) as previously described by us (Naderkhani et al., 2015) .
In vitro mucus binding test
The binding potential of the egg-phospholipid liposomes to mucus was evaluated to determine its interaction with the PVPA barriers. The study was conducted as previously described (Jøraholmen et al., 2017) . The experiment was carried out in triplicate and the binding efficiency of mucus to the liposomes was calculated according to Jøraholmen and colleagues (2017).
Preparation of liposomal formulations
Three different types of liposomal formulations containing either indomethacin (IND), metronidazole (MTR) or naproxen (NPR) were prepared to study the effect of the formulation on drug permeability.
Plain liposomes were obtained using the film hydration technique, according to the method described by Berginc to produce a smaller and more homogeneous size distribution. The sonicated liposome dispersion was stored in the refrigerator for at least 2 hours prior to further use.
Chitosan-coated liposomes were prepared from plain liposomes in the absence of unentrapped drug as previously described (Jøraholmen et al., 2014; Naderkhani et al., 2014a) .
After storage in refrigerator (4-8 °C) overnight, the pH was measured and adjusted to 7.40.
PEGylated liposomes were prepared using Lipoid S100 ( were dialyzed against a medium (PBS, pH 7.40) for 6 hours at room temperature. The volume of PBS was adjusted to assure the solubility of the drugs. Aliquots of the dialyzed liposomes were dissolved in MeOH to free the drug contained in the liposomes and compared with the amount of drug in the medium (unentrapped drug) to calculate the entrapment efficiency for the specific drug. Drugs were quantified as previously described in section 2.4.
Size analysis and zeta potential measurements
The diameter of the dialyzed liposomes containing different drugs was determined using a Malvern Zetasizer Nano ZS (Malvern, Oxford, UK). Two samples for each batch of liposomes were analysed and the diameters calculated from the mean of three measurements for each sample. The liposome dispersions were diluted 1:50 (v/v) in PBS pH 7.40 for plain and PEGylated liposomes, and PBS pH 7.40 and acetic acid 0.1% (1:1 v/v) for the chitosancoated ones, in order to dilute the formulations in their own preparation media. The polydispersity index (PI) of each batch was measured to assess the population's homogeneity.
All liposomal formulations (plain, chitosan-coated and PEGylated) were diluted 1:10
(v/v) in freshly filtered water (0.2 µm filters) to determine the zeta potential using a Malvern Zetasizer Nano ZS (Malvern, Oxford, UK). The disposable folded capillary cells (DTS1070)
were cleaned before the loading of the sample using ethanol and filtered water. Two samples for each batch of formulations were measured in three parallels at room temperature.
Statistical analysis
Statistical analysis was done using GraphPad Prism 7.0 software. Student's t-test was used to detect significant differences between two sets of data (p < 0.05). Comparisons between three or more groups were performed using one-way ANOVA and significance (p < 0.05) was found out using the Bonferroni multiple comparison post hoc test.
Results and discussion
Mucosal tissues, found at various locations in the body, can provide access to both local and systemic drug administration, and are an interesting barrier considering transmucosal delivery (Leal et al., 2017) . Moreover, mucosal administration is seen as one of the most convenient, easy and cost-effective routes (Lechanteur et al., 2017) . However, the mucus layer covering all mucosal tissues represents a barrier that drugs must overcome to reach deeper epithelia or become absorbed. Therefore, it is of key importance to develop reliable in vitro tools able to evaluate the effect of mucus on drug permeability.
The effect of mucus on the PVPA barriers
The mucus-PVPA model is expected to provide fast and reliable means to predict/optimize the permeation of drugs once in contact with mucosal surfaces. Unpurified mucin type III from porcine stomach was employed, since this type of mucin has already been Lagarce, 2014). Moreover, its preparation avoids the degradation that occurs with purified mucin type II; the degradation often leads to a different mesh structure and related different rheological properties compared to native mucus (Groo and Lagarce, 2014). To assess whether the mucus-PVPA can provide reliable evidences on drug permeability, the integrity and functionality of the barriers were investigated. The permeability of the hydrophilic marker calcein in the presence of mucus served as a model. Moreover, the effect of different mucus layer thicknesses on the permeability of a model drug as well as characterization of the interaction between mucus and the PVPA barriers were evaluated.
Permeability of a highly hydrophilic marker
The permeability of the hydrophilic marker calcein was investigated in the presence of different mucin concentrations to study their effect on permeability. This fluorescent marker provides information on potential aqueous pathways in the PVPA barrier (Flaten et al., 2006b ). have found that the greatest reduction in permeability in the presence of mucus was obtained for the hydrophobic drug compared to the hydrophilic one. In our case, considering calcein chemical properties (Table 1) , it was not expected that its permeability should be affected to a great extent by the presence of the mucus layer. Therefore, the lack of changes in permeability in the presence of mucus indicates that calcein is free to diffuse through the mucus layer and to permeate through the PVPA barriers without any considerable interaction with this hydrophilic layer. Moreover, as previously stated, no increase in calcein permeability suggests that the barriers are able to maintain their integrity in the presence of mucus. Furthermore, the electrical resistance remained constant in all of the tested conditions ( Fig. 1 
Characterization of the interaction between mucus and the PVPA barrier
To assess possible disintegration events taking place in the barrier when exposed to mucus, the release of phospholipids from the PVPA barriers into the donor chamber in the presence of mucus (mucin 10 and 40 mg/mL) was quantified and compared to the release in the presence of PBS pH 7.40 on top of the barriers (control). Results (data not shown)
indicated that no significant difference in phospholipid release was found in the presence and absence of mucus. This evidence is in agreement with previous reports on the robustness of the original PVPA barriers (Flaten et al., 2008) and confirms the maintenance of the barriers' integrity and their low degree of interaction with mucus.
To further test the potential interaction between the liposomes in the PVPA barriers and mucus, a mucin binding test was performed. The results obtained (data not shown) confirmed a lack in binding between the two components, especially evident for liposomes with bigger diameter size, comparable to the liposome size on top of the PVPA barrier. This evidence highlights, once again, the lack of changes produced in the PVPA barriers by the mucus layer.
The lack of structural changes in the barriers was also suggested by studies performed using the confocal laser scanning microscopy (CLSM) (results in Supplementary) . The PVPA barriers were investigated to visually examine if the mucus layer would interfere with the barrier's integrity. The micrographs of the cross-sectioned PVPA barriers showed that no aqueous channels were present throughout the barriers, thus confirming the intact integrity of the barriers for all the tested conditions, and that calcein was mainly present in the donor side 
Viscosity, composition and structure of the mucus layer
Since mucin is the major determinant in mucus rheology (Sigurdsson et al., 2013) , the viscosity measurements were performed to study the effect of different mucin concentrations Moreover, a comparison between the viscosity of human saliva and porcine gastric mucin was proposed by and Park and colleagues (Park et al., 2007) . Both human saliva and animal mucin suspensions exhibited similar viscosities with increasing shear rates. Furthermore, an increase in viscosity was found with increasing mucin concentrations, as also found in our analyses.
As previously stated, the composition and concentration of mucin vary in the body depending on the location and function of the mucosal tissue. However, mucin accounts for generally not more than 5% of the mucus components (Griffiths et al., 2010) . Even though the differences in viscosity have to be taken into account when developing a new model, they are only one of the factors affecting the diffusion of drugs through the mucus (Shaw et al., 2005) .
For these reasons, mucin in concentration of 10 mg/mL (viscosity 2.1 mPa*s) was used as a model for mucus in the permeability experiments in this study. These considerations can give us an estimation on how the mucus layer on the PVPA barriers may look like compared to both human and animal mucus and on how particles/formulations could diffuse through this layer, together with the pore size of the mucin mesh. However, it has to be taken into consideration the fact that the structure and composition of the mucus layer differs according to different animal species and different sites of the body (Huckaby and Lai, 2017) and that the mucus-PVPA model so far is aimed to be established as an artificial model for mucosal tissues in general.
Permeability study: the effect of the mucus layer thicknesses
To assess possible changes in drug permeability related to different mucus layer thicknesses on top of the PVPA barriers, the permeability of naproxen was measured in the presence of different volumes of mucus (mucin 10 mg/mL). The thickness of the mucus layer has been reported to be around 600 µm in the human stomach and 50-450 µm in the intestine and colon (Fig. 3, black (Fig. 3 , shaded area) was calculated from the surface area of the filter support. Results showed that there was a significant difference in naproxen's Papp when tested in the presence or absence of mucus (addressed in section 3.2), but there was no significant variation between the different mucus volumes/thicknesses. Therefore, even though the calculated mucus layer thickness for 50 µL of mucin suspension exceeded the physiological range, it was considered the best volume to use. This volume assured that the whole surface area of the barriers will be fully covered with mucus and thus reduced any deviations in the application volume. In conclusion, the use of differently viscous mucus layers (mucin concentration of 10, 20 or 40 mg/mL) did not lead to differences in permeability of all of the tested drugs ( Fig. 4) , even though an increase in viscosity could suggest a slowed-down diffusion through mucus and a lower permeability through the barrier. Therefore, since no direct correlation was found between the concentration of mucin in the mucus layer and the drugs' permeability, mucin 10 mg/mL was chosen as the preferred suspension since it was the easiest to handle from a practical point of view. 
Fig 5
However, if all drugs/marker would have behaved identically in presence of the mucus layer compared to its absence, one could conclude that the rate-limiting factor could be the different diffusive pathway between the original PVPA barriers and the mucus-PVPA model.
Nevertheless, what we have found in our study was that the permeabilities were linked to the chemical structure and physiochemical properties of the drug/marker and to the possible interactions with the mucus layer. For this reason, we believe that the interaction with this layer, rather than the longer diffusive pathway, is the important factor influencing the permeability of the compounds analysed in this study.
Permeability experiments were also carried out on filters covered with mucus only (without the phospholipid vesicle barrier), in order to assess the contribution of the sole mucus layer on the permeability of the drugs. However, it was found that the filters were not able to hold the mucus in the donor compartment (58.82 ± 2.57 % of the total amount of mucus that was placed on top of the filters was found in the acceptor medium after 5 hours).
Due to this, it was not possible to assess the contribution of the mucus layer alone and compare it to the PVPA or mucus-PVPA model. The optimal formulation should be able to assure a high drug concentration at the administration site and consequently a concentration gradient, allowing a passive diffusion across the mucus layer. In this study, plain, chitosan-coated and PEGylated liposomes have been chosen as model drug delivery systems to get their diffusive properties be tested on the novel mucus-PVPA model. We have already tested mucoadhesive and plain liposomes on the original PVPA (Naderkhani et al., 2014a). However, we realized the importance of the presence of mucus to optimize the estimation of the penetration potential of nanosystems.
The effect of the delivery system on drug permeability in the mucus-PVPA
The degree of interaction with mucus largely depends on the size and surface properties of the delivery system. It has been reported that by increasing the particle size of a delivery system from 124 to 560 nm the amount transported in time through the mucus layer significantly decreases due to a stronger steric impediment (Sanders et al., 2000) . Moreover, Takeuchi et al. (2001) have found that 100 nm liposomes are able to diffuse through the mucus layer to a higher extent compared to bigger ones. However, the surface properties of the delivery system could also dictate its interaction with mucus, making the size the In our study, plain, chitosan-coated and PEGylated liposomes were prepared incorporating three different drugs, respectively ( Table 2 ). The size of the liposomes ranged between 100 and 200 nm and the liposome dispersions exhibited a bimodal size distribution with varying polydispersity indexes (PI), depending on the formulation. The zeta potential varied between the different formulations and was dependant on the incorporated drug.
However, the coating process led to an increase in zeta potential for the chitosan-coated formulations, as expected (Berginc et al., 2014) . It has to be highlighted that the PEGylated 
Table 2
The permeability of metronidazole, indomethacin and naproxen from different liposome formulations (Fig.6 ) indicated decreased permeability for liposomally-associated drugs compared to drugs in solution, confirming that liposomes assured a sustained release of the associated drugs. This is a very important feature considering prolonged release of drugs at the administration site, e.g. vaginal site (Jøraholmen et al., 2014) .
For metronidazole-containing liposomes, the drug permeability did not vary between the different formulations in the absence of mucus, suggesting that the chitosan coating and PEGylation processes had a negligible effect on drug release from the liposomes compared to the plain ones, evidence supported by the results obtained by Chen et al. (2013) . However, in the presence of the mucus layer, metronidazole's permeability changed according to the type of liposome formulation. In fact, chitosan-coated liposomes displayed a lower permeability of the drug compared to the plain ones, suggesting that the potential interaction between mucus and the chitosan-coating could slow down the permeation process of metronidazole, whereas
PEGylated liposomes could easily penetrate through the mucus layer, contributing to a higher permeability. These results can be also explained by the different zeta potentials of the three formulations. Chitosan-coated liposomes, bearing a slightly positive zeta potential, could interact with the negatively charged mucus leading to a mucoadhesive effect, whereas the PEGylated liposomes, having a slightly negative zeta potential, could freely diffuse through the mucus layer. These results are supported by the findings of Chen and colleagues (2013), who clearly depicted the different mucus penetration potentials of plain phosphatidylcholine, chitosan-coated and Pluronic®-modified liposomes in ex vivo penetration studies. Their in vivo pharmacokinetic study further demonstrated that the Pluronic®-modified formulation (bearing a zeta potential of -4 mV) could provide the best oral absorption profile for the chosen drug, indicating that the ex vivo data correlate well with the in vivo one.
The indomethacin-and naproxen-containing liposomes, exhibited a different penetration behaviour; indomethacin-containing plain, chitosan-coated and PEGylated liposomes were all found to be negatively charged (-25, -19 and -10 mV, respectively), a 26 feature that could lead to a lack of significant differences in the diffusion potential of the formulation and permeability of the drug. On the other hand, for the naproxen-containing liposomes, the PEGylation lead to an increase in permeability in the absence of mucus, suggesting an intrinsic penetration behaviour of the formulation. These deviations from the trends described above for the metronidazole-containing liposomes can be ascribed to the complexity of the physicochemical characteristics of the specific liposomal formulation, highlighting the problem/challenge of generalization when studying mucus diffusion properties and permeability potentials of different types of formulations (Fabiano et al., 2017; Netsomboon and Bernkop-Schnürch, 2016) . Moreover, we found that the surface potential of the liposomes prepared varied according to the drug incorporated. Therefore, the mucopenetrating or mucoadhesive behaviour could mainly be linked to the specific zeta potential of the formulation. The permeability of the drugs depends on numerous factors including the penetration potential of the liposome formulation through the mucus layer and the interaction with it, the vesicle surface properties and size, but also the release of the drug from the delivery system, the chemical and structural properties of the specific compound and the drug equilibrium between the different layers. This confirms the high importance and need to have reliable in vitro permeability models able to predict the effect of mucus on the permeability of both drugs in solutions and in more complicated formulations.
Fig. 6
Conclusions
The novel mucus-PVPA model was developed and exploited to better mimic the in vivo the micrographs. The micrographs were superimposed using Volocity ® v.6.3 software (PerkinElmer, MA, USA).
Results
In a previous study, Flaten and colleagues have analysed via confocal electron scanning microscopy the filters composing the PVPA barriers without the addition of the liposomes 
Fig. S2
Fig . S2 indicates that no aqueous channels were present after the exposure to the lowest concentration of mucus suspension.
Fig. S3
As it can be observed from Fig. S3 , calcein was more abundant as compared to previous results ( Fig. S1 and S2 ). The first cross-section (a) indicates a barrier similar to the one when PVPA barrier was exposed to calcein solution ( Fig. S1 and S2 ). In the second micrograph and cross-section (b) calcein was visible in a higher concentration in the donor side of the barrier.
However, no significant breaches in the barrier were observed, suggesting that the barrier's integrity was maintained also in the presence of the highest concentration of mucus suspension.
